[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06581120":3,"trial-entities:NCT06581120":90,"trial-summary:NCT06581120":95},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":24,"study_type":29,"primary_purpose":17,"phases":30,"enrollment_info":31,"interventions":34,"primary_outcomes":48,"secondary_outcomes":53,"sex":54,"minimum_age":55,"maximum_age":56,"healthy_volunteers":57,"eligibility_criteria":58,"std_ages":73,"locations":76,"central_contacts":86,"overall_officials":87,"references":88,"see_also_links":89},"NCT06581120","2024-0304","GLP_1 RA Ultrasound Study","Assessment of Gastric Contents in Patients Taking Glucagon-Like Peptide-1 Receptor Agonists: a Prospective Observational Cross-sectional Study","ENROLLING_BY_INVITATION","2026-07","2024-11","2024-11-07","2024-07-08","Children's Hospital Medical Center, Cincinnati","OTHER",false,"The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.",null,[19,20,21,22,23],"Glucagon Like Peptide-1 (GLP-1","Delayed Gastric Emptying","Risk of Aspiration","Diabetes","Morbid Obesity",[25,26,27,28],"GLP-1","Glucagon like Peptide 1","Aspiration","Gastric empty","OBSERVATIONAL",[],{"count":32,"type":33},100,"ESTIMATED",[35,40],{"type":36,"name":37,"description":38,"armGroupLabels":39},"DRUG","Glucagon-Like Peptide-1 receptor agonists","GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA\u002Fglucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.",[25],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":46},"DIAGNOSTIC_TEST","Point of Care Gastric Ultrasound","A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.",[45,25],"Control",[47],"POGUS",[49],{"measure":50,"description":51,"timeFrame":52},"Aspiration Risk determined by POGUS","Difference between control group and GLP-1 group. Measured by Gastric contents during Point of Care Gastric Ultrasound.","Two years",[],"ALL","10 Years","25 Years",true,{"inclusion":59,"exclusion":64,"raw_text":72},[60,61,62,63],"Body Mass Index over 35","Type 2 Diabetes","Currently taking GLP01 RA agonist (for GLP 1 group)","Not taking GLP-1 RA agonist (for control group)",[65,66,67,68,69,70,71],"Diagnosis of gastroparesis","patient refusal to participate","Previous gastric bypass or any other gastric surgery","Currently on peritoneal dialysis","Abdominal pathology","Gastro-intestinal obstruction","Pregnancy","Inclusion Criteria:\n\n* Body Mass Index over 35\n* Type 2 Diabetes\n* Currently taking GLP01 RA agonist (for GLP 1 group)\n* Not taking GLP-1 RA agonist (for control group)\n\nExclusion Criteria:\n\n* Diagnosis of gastroparesis\n* patient refusal to participate\n* Previous gastric bypass or any other gastric surgery\n* Currently on peritoneal dialysis\n* Abdominal pathology\n* Gastro-intestinal obstruction\n* Pregnancy",[74,75],"CHILD","ADULT",[77],{"facility":78,"city":79,"state":80,"zip":81,"country":82,"geoPoint":83},"Cincinnati Children's Hospital","Cincinnati","Ohio","45299","United States",{"lat":84,"lon":85},39.12711,-84.51439,[],[],[],[],{"nct_id":4,"conditions":91,"biomarkers":94},[92,93],"Obesity","Type 2 Diabetes Mellitus",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]